A Study in Participants With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Lucentis® Prefilled Syringe

The purpose of this study is to assess the ability of health care providers (HCPs) to follow
the instructions for use (IFU) to prepare and administer a Lucentis PFS ITV injection dose
to patients.

Inclusion Criteria:

Ocular

- Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the
retina specialist

Exclusion Criteria:

Concurrent Ocular Conditions

- Participants legally blind in one or both eyes

- History of or any current clinically relevant intraocular inflammation or ocular
inflammatory reaction (any grading from trace and greater is excluded), including
non-infectious uveitis or uveitis, or sterile inflammatory reaction after the past
ITV injections with any agent

- Active disorder of ocular adnexa and skin in the study eye, including ocular surface
infections

- History of or any current indication of excessive bleeding and recurrent hemorrhages,
including any prior excessive intraocular (including subconjunctival) bleeding or
hemorrhages after ITV injection or intraocular procedures

- Uncontrolled intraocular pressure greater than (>) 25 millimeter of mercury (mmHg) in
the study eye (uncontrolled means that it occurs even with intraocular
pressure-lowering therapy)

- Use of therapies that are known to be toxic to any ocular tissues within the 6 months
prior to enrollment

Prior Ocular Therapies

- Treatment with any ITV injection within the 27 days prior to Day 1

- Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug
release device implantation (approved or investigational) in the study eye at any
time during the past 3 months

General

- Receipt of any systemic (non-ocular) investigational drug within 3 months prior to
Day 1

- Current systemic coagulation or bleeding disorders and history of recurrent
hemorrhages

- Intolerance or known reaction to prior biological therapies

- History of other diseases or physical or laboratory examination findings that per the
retina specialist represent a contraindication to ranibizumab use in the patient or
may represent an unwarranted patient risk.

- Uncontrolled hypertension (systolic >160 mmHg and/or diastolic >100 mmHg while
sitting)

- Current systemic infectious disease or a therapy for active infectious disease

- Pregnant or lactating